Ratiopharm up for grabs
This article was originally published in The Tan Sheet
Executive Summary
The Merckle Group, the parent of German OTC and generic drug firm Ratiopharm, agrees with investors at VEM VV GmbH to arrange for a bridge loan from Merckle's creditor banks in order to sell Ratiopharm. The Jan. 7 decision follows the suicide of Merckle Group founder, Adolf Merckle, which was linked to his and the company's financial crises. The sale likely will take several months, Ratiopharm says
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.